143 related articles for article (PubMed ID: 38625642)
21. Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma.
Yeh S; Karne NK; Kerkar SP; Heller CK; Palmer DC; Johnson LA; Li Z; Bishop RJ; Wong WT; Sherry RM; Yang JC; Dudley ME; Restifo NP; Rosenberg SA; Nussenblatt RB
Ophthalmology; 2009 May; 116(5):981-989.e1. PubMed ID: 19410956
[TBL] [Abstract][Full Text] [Related]
22. Establishment and large-scale expansion of minimally cultured "young" tumor infiltrating lymphocytes for adoptive transfer therapy.
Itzhaki O; Hovav E; Ziporen Y; Levy D; Kubi A; Zikich D; Hershkovitz L; Treves AJ; Shalmon B; Zippel D; Markel G; Shapira-Frommer R; Schachter J; Besser MJ
J Immunother; 2011 Mar; 34(2):212-20. PubMed ID: 21304398
[TBL] [Abstract][Full Text] [Related]
23. Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma.
Hall MS; Mullinax JE; Cox CA; Hall AM; Beatty MS; Blauvelt J; Innamarato P; Nagle L; Branthoover H; Wiener D; Schachner B; Martinez AJ; Richards AD; Rich CJ; Colón Colón M; Schell MJ; Teer JK; Khushalani NI; Weber JS; Mulé JJ; Sondak VK; Pilon-Thomas S; Sarnaik AA
Clin Cancer Res; 2022 Dec; 28(24):5317-5329. PubMed ID: 36215121
[TBL] [Abstract][Full Text] [Related]
24. PD-L1 status does not predict the outcome of BRAF inhibitor therapy in metastatic melanoma.
Schaper-Gerhardt K; Okoye S; Herbst R; Ulrich J; Terheyden P; Pföhler C; Utikal JS; Kreuter A; Mohr P; Dippel E; Satzger I; Sucker A; Schadendorf D; Ugurel S; Gutzmer R
Eur J Cancer; 2018 Jan; 88():67-76. PubMed ID: 29195116
[TBL] [Abstract][Full Text] [Related]
25. Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma.
Saberian C; Amaria RN; Najjar AM; Radvanyi LG; Haymaker CL; Forget MA; Bassett RL; Faria SC; Glitza IC; Alvarez E; Parshottam S; Prieto V; Lizée G; Wong MK; McQuade JL; Diab A; Yee C; Tawbi HA; Patel S; Shpall EJ; Davies MA; Hwu P; Bernatchez C
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34021033
[TBL] [Abstract][Full Text] [Related]
26. Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up.
van den Berg JH; Heemskerk B; van Rooij N; Gomez-Eerland R; Michels S; van Zon M; de Boer R; Bakker NAM; Jorritsma-Smit A; van Buuren MM; Kvistborg P; Spits H; Schotte R; Mallo H; Karger M; van der Hage JA; Wouters MWJM; Pronk LM; Geukes Foppen MH; Blank CU; Beijnen JH; Nuijen B; Schumacher TN; Haanen JBAG
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32753545
[TBL] [Abstract][Full Text] [Related]
27. Predictors of tumor-infiltrating lymphocyte efficacy in melanoma.
Zikich D; Schachter J; Besser MJ
Immunotherapy; 2016; 8(1):35-43. PubMed ID: 26653685
[TBL] [Abstract][Full Text] [Related]
28. TIL in Melanoma-Similar Approaches, Different Results, Unanswered Questions.
Sznol M
Clin Cancer Res; 2021 Oct; 27(19):5156-5157. PubMed ID: 34413160
[TBL] [Abstract][Full Text] [Related]
29. Manipulating the tumor microenvironment ex vivo for enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy.
Chacon JA; Sarnaik AA; Chen JQ; Creasy C; Kale C; Robinson J; Weber J; Hwu P; Pilon-Thomas S; Radvanyi L
Clin Cancer Res; 2015 Feb; 21(3):611-21. PubMed ID: 25472998
[TBL] [Abstract][Full Text] [Related]
30. Tissue Harvesting for Adoptive Tumor Infiltrating Lymphocyte Therapy in Metastatic Melanoma.
Zippel D; Friedman-Eldar O; Rayman S; Hazzan D; Nissan A; Schtrechman G; Markel G; Schachter J; Itzhaki O; Besser MJ
Anticancer Res; 2019 Sep; 39(9):4995-5001. PubMed ID: 31519606
[TBL] [Abstract][Full Text] [Related]
31. Cobimetinib: First Global Approval.
Garnock-Jones KP
Drugs; 2015 Oct; 75(15):1823-30. PubMed ID: 26452567
[TBL] [Abstract][Full Text] [Related]
32. Treatment with tumour infiltrating lymphocytes and interleukin-2 in patients with metastatic melanoma: a pilot study.
Baars JW; Fonk JC; Scheper RJ; von Blomberg-van der Flier BM; Bril H; von Valk P; Pinedo HM; Wagstaff J
Biotherapy; 1992; 4(4):289-97. PubMed ID: 1622742
[TBL] [Abstract][Full Text] [Related]
33. Proliferative, phenotypic and functional and molecular characteristics of tumour-infiltrating lymphocytes obtained from unselected patients with malignant melanomas and expanded in vitro in the presence of recombinant interleukin-2.
Melioli G; Guastella M; Semino C; Meta M; Pietra G; Ponte M; Queirolo P; Sertoli MR; Martini L; Reali UM
Melanoma Res; 1994 Apr; 4(2):127-33. PubMed ID: 8069098
[TBL] [Abstract][Full Text] [Related]
34. Adjuvant adoptive immunotherapy with tumour-infiltrating lymphocytes and modulated doses of interleukin-2 in 22 patients with melanoma, colorectal and renal cancer, after radical metastasectomy, and in 12 advanced patients.
Ridolfi R; Flamini E; Riccobon A; De Paola F; Maltoni R; Gardini A; Ridolfi L; Medri L; Poletti G; Amadori D
Cancer Immunol Immunother; 1998 Jun; 46(4):185-93. PubMed ID: 9671141
[TBL] [Abstract][Full Text] [Related]
35. Multiplex Quantitative Analysis of Tumor-Infiltrating Lymphocytes and Immunotherapy Outcome in Metastatic Melanoma.
Wong PF; Wei W; Smithy JW; Acs B; Toki MI; Blenman KRM; Zelterman D; Kluger HM; Rimm DL
Clin Cancer Res; 2019 Apr; 25(8):2442-2449. PubMed ID: 30617133
[TBL] [Abstract][Full Text] [Related]
36. Study of tumor-infiltrating lymphocytes for adoptive therapy of renal cell carcinoma (RCC) and metastatic melanoma: sequential proliferation of cytotoxic natural killer and noncytotoxic T cells in RCC.
Hayakawa K; Salmeron MA; Parkinson DR; Markowitz AB; von Eschenbach AC; Legha SS; Balch CM; Ross MI; Augustus LB; Itoh K
J Immunother (1991); 1991 Oct; 10(5):313-25. PubMed ID: 1790139
[TBL] [Abstract][Full Text] [Related]
37. Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study.
Chandran SS; Somerville RPT; Yang JC; Sherry RM; Klebanoff CA; Goff SL; Wunderlich JR; Danforth DN; Zlott D; Paria BC; Sabesan AC; Srivastava AK; Xi L; Pham TH; Raffeld M; White DE; Toomey MA; Rosenberg SA; Kammula US
Lancet Oncol; 2017 Jun; 18(6):792-802. PubMed ID: 28395880
[TBL] [Abstract][Full Text] [Related]
38. Impact of clinical and pathologic features on tumor-infiltrating lymphocyte expansion from surgically excised melanoma metastases for adoptive T-cell therapy.
Joseph RW; Peddareddigari VR; Liu P; Miller PW; Overwijk WW; Bekele NB; Ross MI; Lee JE; Gershenwald JE; Lucci A; Prieto VG; McMannis JD; Papadopoulos N; Kim K; Homsi J; Bedikian A; Hwu WJ; Hwu P; Radvanyi LG
Clin Cancer Res; 2011 Jul; 17(14):4882-91. PubMed ID: 21632855
[TBL] [Abstract][Full Text] [Related]
39. Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies.
Besser MJ; Shapira-Frommer R; Itzhaki O; Treves AJ; Zippel DB; Levy D; Kubi A; Shoshani N; Zikich D; Ohayon Y; Ohayon D; Shalmon B; Markel G; Yerushalmi R; Apter S; Ben-Nun A; Ben-Ami E; Shimoni A; Nagler A; Schachter J
Clin Cancer Res; 2013 Sep; 19(17):4792-800. PubMed ID: 23690483
[TBL] [Abstract][Full Text] [Related]
40. Enrichment of CD8+ cells from melanoma tumor-infiltrating lymphocyte cultures reveals tumor reactivity for use in adoptive cell therapy.
Prieto PA; Durflinger KH; Wunderlich JR; Rosenberg SA; Dudley ME
J Immunother; 2010 Jun; 33(5):547-56. PubMed ID: 20463593
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
